Group 1 - The company, Shouyao Holdings, announced the reappointment of Tianjian Accounting Firm (Special General Partnership) as the auditor for its financial statements and internal controls for the fiscal year 2025 [2]

Group 1 - The company disclosed its half-year report on August 27, revealing a revenue of 2 million yuan, a year-on-year decrease of 47.37% [1] - The net profit attributable to shareholders was a loss of 104 million yuan, compared to a loss of 103 million yuan in the same period last year [1] - The basic earnings per share were reported at -0.7 yuan [1]

格隆汇8月27日丨首药控股(688197.SH)披露半年报，公司上半年实现营业收入200万元，同比下降 47.37%；归属于上市公司股东的净利润亏损1.04亿元，上年同期亏损1.03亿元；基本每股收益-0.7元。 ...

证券代码：688197 证券简称：首药控股 公告编号：2025-018 首药控股（北京）股份有限公司 （一）审议通过了《关于公司<2025 年半年度报告>及其摘要的议案》 表决结果：7 票赞成；0 票弃权；0 票反对。 关于第二届董事会第十次会议决议的公告 公 司 《 2025 年 半 年 度 报 告 》 详 见 同 日 披 露 于 上 海 证 券 交 易 所 网 站 （www.sse.com.cn，下同）的公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 首药控股（北京）股份有限公司（以下称"公司"）第二届董事会第十次会 议于2025年8月26日在公司会议室以现场方式召开。本次会议的通知于2025年8 月15日以专人送达、电子邮件等方式送达全体董事。会议应出席董事7人，实际 出席董事7人，全体监事、董事会秘书现场列席会议。会议由董事长李文军先生 主持。会议召集及召开程序符合《公司法》和《公司章程》的有关规定，会议 决议合法、有效。 二、董事会会议审议情况 公司《2025 年半年度报告摘要》 ...

Fundraising Overview - The company raised a total of RMB 1,483,482,000.00 through the issuance of 37,180,000 shares at a price of RMB 40.00 per share, with net proceeds after expenses amounting to RMB 1,378,838,926.21 [1][2] - As of June 30, 2025, the company has utilized RMB 1,102,682,065.36 of the raised funds, with RMB 103,363,523.27 used in the first half of 2025 [1][2] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure effective use and management of the raised funds [1][2] - A tripartite supervision agreement has been signed with banks to regulate the storage and use of the funds, ensuring compliance with the regulations [1][2] Fund Utilization - The funds have been allocated primarily to innovation drug research and development (R&D) projects, with RMB 653,160,459.45 used for this purpose [1][2] - The company has also utilized RMB 429,759,485.91 for working capital and has temporarily set aside RMB 300,000,000.00 for cash management [1][2] Cash Management - The company has engaged in cash management using temporarily idle funds, with a maximum limit of RMB 80,000,000.00 approved for investment in safe and liquid financial products [3][4] - As of June 30, 2025, the company has invested RMB 300,000,000.00 in structured deposits and large-denomination certificates of deposit [7][8] Project Adjustments - The company has made adjustments to its fundraising projects, including the addition of two sub-projects under the "New Drug R&D Project" and the termination of the base project, reallocating unused funds to support R&D efforts [10][11] - The company has also decided to terminate the clinical development of a specific drug candidate, SY-1530, based on market assessments and resource allocation [10][11] Compliance and Reporting - The company has adhered to the regulatory requirements for fundraising and has disclosed the use and management of funds accurately and timely, with no violations reported [10][11]

证券代码：688197 证券简称：首药控股 公告编号：2025-022 首药控股（北京）股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ? 拟续聘的会计师事务所名称：天健会计师事务所（特殊普通合伙） ? 本事项尚需提交公司 2025 年第一次临时股东大会审议 首药控股（北京）股份有限公司（以下简称"公司"）于2025年8月26日召开 第二届董事会第十次会议，会议审议通过了《关于续聘2025年度财务报表及内 部控制审计机构的议案》。现将有关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 | 天健会计师事务所（特殊普通合伙）（以下简称"天健所"） | | 事务所名称 | | --- | --- | --- | | 2011年7月18日 | 组织形式 特殊普通合伙 | 成立日期 | | 注册地址 浙江省杭州市西湖区灵隐街道西溪路128号 | | | | 首席合伙人 | 钟建国 2024年末合伙人数量 241人 | | | 注册会计师 | 2,356人 ...

Core Viewpoint - Shouyao Holdings (Beijing) Co., Ltd. is undergoing significant corporate governance changes, including a change of registered address, the cancellation of the supervisory board, and amendments to the Articles of Association to align with updated regulations and improve governance structure [1][2][3]. Group 1: Change of Registered Address - The registered address of Shouyao Holdings is changing from "No. 10 Ronghua Middle Road, Beijing Economic and Technological Development Zone, Building 1, A Seat, 22nd Floor, Room 2205" to "No. 10 Ronghua Middle Road, Beijing Economic and Technological Development Zone, Building 1, 19th Floor, Unit 2202-2" [1]. Group 2: Cancellation of Supervisory Board - The company will no longer have a supervisory board, with the audit committee of the board of directors assuming the supervisory functions as per the latest revisions of the Company Law and related regulations [1][2]. - The current supervisory board members will continue their roles until the first extraordinary general meeting of shareholders in 2025, where the cancellation will be formally approved [2]. Group 3: Amendments to Articles of Association - The Articles of Association will be systematically revised to enhance the governance structure, including the removal of references to the supervisory board and the introduction of terms related to the audit committee [1][2]. - Key changes include the unification of terms from "shareholders' meeting" to "shareholders' assembly" and the removal of all references to "supervisors" and "supervisory board" [2]. - The revised Articles of Association will be disclosed on the Shanghai Stock Exchange website [2]. Group 4: Authorization for Changes - The board of directors will seek authorization from the shareholders' meeting to allow management to handle the necessary business registration changes and amendments to the Articles of Association [3].

Core Viewpoint - The company is actively implementing its "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on accelerating drug development, enhancing financial management, and improving corporate governance to increase shareholder value and maintain compliance with regulatory requirements [1][12]. Group 1: Drug Development and Commercialization - The company has made significant progress in its core drug pipeline, with multiple candidates in various clinical development stages targeting key oncogenic drivers such as ALK, RET, and KRAS (G12C) [2][3]. - The key Phase III clinical study of SY-5007 for RET fusion-positive NSCLC has met its primary endpoint, demonstrating significant anti-tumor activity [3]. - The company is advancing the development of SY-3505, a third-generation ALK inhibitor, with key Phase II and III studies completed, and patient follow-ups are ongoing [3][4]. - SY-5933 has shown promising pharmacokinetic properties and anti-tumor activity in patients with KRAS (G12C) mutations, with good tolerability observed [4][5]. - The company is exploring combination therapies with SY-5933 and SY-707, showing enhanced anti-tumor effects in preclinical models [6]. Group 2: Early Pipeline and International Collaboration - The company is committed to early-stage research, presenting key data on four projects at the 2025 AACR annual meeting, including a fourth-generation ALK inhibitor and various other targeted therapies [7]. - Plans are in place to present data on SY-5007 at the 2025 ESMO annual meeting, highlighting the company's ongoing commitment to international academic exchange [7]. Group 3: Infrastructure Development - The company has signed an economic development cooperation agreement to invest up to 787 million yuan in a new drug research and industrialization base at Bio Park, enhancing its R&D and production capabilities [8]. Group 4: Financial Management - As of mid-2025, the company reported total assets of 819.45 million yuan and equity attributable to shareholders of 704.64 million yuan, with no interest-bearing debt, indicating a strong financial position [9]. - The company achieved cash management income of 9.44 million yuan through prudent investment strategies while ensuring liquidity and safety [10]. Group 5: Corporate Governance - The company has strengthened its governance structure, holding multiple board meetings and enhancing communication with key personnel to ensure compliance and effective oversight [11]. - Amendments to the company's governance documents are underway to align with new regulations, aiming to clarify responsibilities and improve governance efficiency [12]. Group 6: Investor Relations and Information Disclosure - The company emphasizes investor communication, participating in nearly 60 investor engagement activities and ensuring transparent information disclosure [12][13]. - A total of 2 regular reports and 17 temporary announcements were disclosed in the first half of 2025, maintaining high standards of transparency and compliance [13][14].

Key Points - The company, Shouyao Holdings, will hold a collective performance briefing for the first half of 2025 on September 16, 2025, from 15:00 to 17:00 [1][2] - The briefing will be conducted online through the Shanghai Stock Exchange's roadshow center, allowing investors to interact and ask questions [1][3] - Key personnel attending the meeting include the Chairman and General Manager, Li Wenjun, along with other executives and independent directors [2]

General Principles - The purpose of the implementation rules is to enhance the company's risk management, internal control, and audit system, ensuring effective supervision of financial information and protecting shareholder rights [1][2] - The Audit Committee is established as a specialized working body of the Board of Directors, responsible for reviewing financial information and supervising internal and external audits [1][2] Composition of the Audit Committee - The Audit Committee consists of three members appointed by the Board of Directors, with a majority being independent directors and a professional accountant serving as the chairperson [2][3] - Members must possess relevant professional knowledge and experience to effectively oversee and evaluate audit work [2][3] Responsibilities and Authority - The Audit Committee is responsible for reviewing financial information, supervising external audit work, and assessing internal controls [4][5] - Key responsibilities include proposing the hiring or replacement of external auditors, reviewing financial reports, and ensuring compliance with laws and regulations [4][5][6] - The Committee must approve certain matters before submission to the Board, including financial disclosures and the hiring of auditors [10][11] Internal Audit Oversight - An internal audit department operates under the Audit Committee, which supervises its activities and ensures effective internal control [7][8] - The Committee is tasked with reviewing the internal audit plan and ensuring that significant issues are reported to the Board [8][9] Meeting Procedures - The Audit Committee must meet at least quarterly, with additional meetings called as necessary [13][14] - Decisions require a majority vote, and members must disclose any conflicts of interest [26][27] Reporting and Accountability - The Audit Committee is accountable to the Board and must report on its activities, including evaluations of external auditors [15][16] - The Committee can propose the convening of temporary shareholder meetings if necessary [21][22] Implementation and Amendments - The rules take effect upon approval by the Board and can be amended following the same process [33][34]